Title: The Innovative Contributions of Andres Mannik
Introduction
Andres Mannik is a notable inventor based in Estonia. He has made significant strides in the field of biotechnology, particularly in the study of Human Papilloma Virus (HPV) replication. His work focuses on developing methods and systems to identify compounds that can inhibit HPV, which is crucial for advancing therapeutic options.
Latest Patents
Mannik's latest patents include an "Assay System To Identify HPV Replication Inhibitors In HT-Screen." This invention provides a U2OS-based model system using luciferase reporters to monitor the genome replication of alpha and beta HPVs. The modified U2OS cell line expresses Firefly luciferase to measure the toxicity of screened compounds. Additionally, the patent includes HPV18, HPV16, and HPV5 marker genomes that express Renilla luciferase under the control of viral promoters to measure changes in viral copy number. This ready-to-use model system is capable of being utilized in high-throughput screens to identify compounds that inhibit the initial amplification and stable maintenance, as well as the vegetative phase of various HPV subtypes.
Another significant patent is the "Method And Kit For Identifying Compounds Capable Of Inhibiting Human Papilloma Virus Replication." This invention outlines a method and kit for identifying compounds that can inhibit HPV replication. The method involves inserting HPV genomic or subgenomic DNA into a cell line that supports HPV DNA replication. The influence of a compound on the replication of HPV DNA is then determined. The U2OS cell line has been identified as a feasible host for HPV DNA replication, making it suitable for the propagation of genomes of mucosal and cutaneous tissue-specific HPVs. This method enables screening for factors that inhibit HPV DNA replication at different phases of the HPV life cycle, which can be instrumental in pharmacological research and the development of new drug candidates.
Career Highlights
Throughout his career, Mannik has worked with various companies, including Fit Biotech Oyj Plc and Icosagen Cell Factory. His experience in these organizations has contributed to his expertise in biotechnology and his innovative approaches to HPV research.
Collaborations
Mannik has collaborated with notable individuals in his field, including Kai Krohn and Vesna Blazevic. These collaborations have likely enhanced his research and development efforts in HPV-related studies.
Conclusion
And